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Aims To examine long-term healthcare utilization and costs of patients with stable coronary artery disease (SCAD).
Methods
and results
Linked cohort study of 94 966 patients with SCAD in England, 1 January 2001 to 31March 2010, identified from primary
care, secondary care, disease, and death registries. Resource use and costs, and cost predictors by time and 5-year
cardiovascular disease (CVD) risk profile were estimated using generalized linear models. Coronary heart disease hos-
pitalizations were 20.5% in the first year and 66% in the year following a non-fatal (myocardial infarction, ischaemic or
haemorrhagic stroke) event. Mean healthcare costs were £3133 per patient in the first year and £10 377 in the year
following a non-fatal event. First-year predictors of cost included sex (mean cost £549 lower in females), SCAD diag-
nosis (non-ST-elevation myocardial infarction cost £656more than stable angina), and co-morbidities (heart failure cost
£657 more per patient). Compared with lower risk patients (5-year CVD risk 3.5%), those of higher risk (5-year CVD
risk 44.2%) had higher 5-year costs (£23 393 vs. £9335) and lower lifetime costs (£43 020 vs. £116 888).
Conclusion Patients with SCAD incur substantial healthcare utilization and costs, which varies and may be predicted by 5-year CVD
risk profile. Higher risk patients have higher initial but lower lifetime costs than lower risk patients as a result of shorter
life expectancy. Improved cardiovascular survivorship among an ageing CVD population is likely to require stratified
care in anticipation of the burgeoning demand.
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Introduction
Improved survival coupled with a decline in the incidence of acute
myocardial infarction (AMI)1,2 has dramatically changed the pattern
of healthcare use over recent years.3,4 Nowadays, patients with
stable coronary artery disease (SCAD), including patients with
stable angina and those who have become stable after acute
coronary syndrome (ACS),5,6 are older and living longer and so
make greater use of healthcare resources. Patients with SCAD
might be considered to have ‘fallen off the radar’ of clinical interest:
no longer in cardiac rehabilitation [mainly offered to those immedi-
ately after AMI or coronary artery bypass grafting (CABG)], dis-
charged from ongoing specialist care, and with suboptimal drug
compliance, adherence, and persistence.7 Such patients, however,
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vary widely in their risk of subsequent AMI or coronary death
(10-fold, between top and bottom deciles of risk),8 which will
clearly have differential resource implications.
While previous studies of resource use and cost have taken as a
starting point AMI,9,10 there is a paucity of information about the con-
temporary use and associated costs of healthcare beyond the initial
hospital stay. In addition, existing studies in the area have been limited
in a number of ways. First, as a result of the nature of their samples,
they are not population based and do not reflect contemporary and
routine clinical practice.11 Second, they use overly simplistic models,
typically restricting their analysis to a subset of SCAD index events
and not evaluating how the pattern of healthcare resource use
changes following a first post-SCAD myocardial infarction (MI) or
stroke.9,10 Third, no study has evaluated resource utilization and costs
according to baseline cardiovascular risk, despite the importance of
this information in improving decision-making and ensuring more ef-
ficient use of limited healthcare resources. Fourth, longer term and
particularly lifetime implications of SCAD have not been quantified.
These knowledge gaps have a number of important ramifications.
They create uncertainty for those who need to forecast future care
needs, restrain the research and development of new technologies
and treatments for SCAD, and limit informed clinical decision-
making. To address these limitations, our study aimed to (i) deter-
mine healthcare utilization and the associated costs in the first year
with SCAD and in the year following a first non-fatal event (i.e. AMI,
ischaemic or haemorrhagic stroke), (ii) study predictors of costs in
the first year of SCAD, and (iii) estimate the 5-year and lifetime costs
among patients at low and high risk of subsequent events and
coronary heart disease (CHD) death.
Methods
Data set and patient population
The ClinicAl research using Linked Bespoke studies and Electronic Re-
cords (CALIBER) e-health database was the data resource for this study.
CALIBER links patient records from four different data sources: Clinical
Practice Research Database (CPRD), Myocardial Ischaemia National
Audit Project (MINAP) registry, Hospital Episodes Statistics (HES),
and the Office for National Statistics. The data of CPRD were used to
obtain heart rate measurements, demographic variables, and other risk
factors. Primary care practices that provide valuable data to CPRD and
cover 4% of UK population are representative in terms of demo-
graphic parameters such as gender, age, and ethnicity12,13 and overall
mortality14 and have been validated for epidemiological research. A de-
scription of the CALIBER approach has been presented elsewhere.15
Classification algorithms combining Read, International Classification
of Disease 10 (ICD-10), drug, and procedure codes to define risk factors
and endpoints are available at http://www.caliberresearch.org/portal/.
Eligible patients were those with a diagnosis of stable angina, patients
with a diagnosis of ACS within the study period (unstable angina or
AMI), or those with a diagnosis of CHD in which there is no further spe-
cification of whether it is angina orMI (other CHD). Study start datewas
calculated from the date of diagnosis of stable angina or other CHD or
from 6 months after an ACS or coronary intervention. The period of
6 months was chosen to differentiate long-term prognosis from the
high-risk period that typically follows an ACS or revascularization. Diag-
noses were identified in CPRD, HES, or MINAP records according to
definitions given in the CALIBER data manual.15 Patients were only
eligible for the study during the period they were actively registered
at a CPRD practice that was collecting up-to-standard data (according
to CPRD measures of data quality and completeness), with follow-up
ending if a patient transferred out of a CPRD practice. Full details of
the cohort are available elsewhere.8
Healthcare utilization
Healthcare utilization extracted from the data set included primary care
consultations, pharmaceutical prescriptions, inpatient stays, and diag-
nostic tests. Primary care consultations included all contacts between
the patient and healthcare professionals captured in the CPRD data
set. Prescription data were available from the CPRD data set and distin-
guished between drugs that were cardiovascular disease (CVD)-related
and those that were not. Inpatient stays extracted fromHES were based
on Health Resource Group (HRG) codes and defined as CHD, CVD
(including CHD and broader HRGs), or non-CVD related based on
ICD-10 codes. Diagnostic tests as recorded in the primary care data
set but not outpatient consultations were also extracted, the latter
being due to the absence of outpatient HES data linkage.
Costs
All costs were calculated from the perspective of the UK National
Health Service (NHS) in pound sterling based on 2011/12 prices. Costs
were calculated by combining healthcare utilization data from CALIBER
with associated unit costs that were taken from published UK
sources.16–18 For hospitalizations, costs are calculated based on finished
consultant episodes in HES. Costs are presented in terms of total
healthcare costs (all costs incurred), CHD costs (all CHD-related hos-
pitalization costs, CVD-related drugs, and all primary care and diagnos-
tic costs), and CVD costs (all CVD-related hospitalization costs,
CVD-related drugs, and all primary care and diagnostic costs).
Analytical methods
Estimates of healthcare utilization and costs were calculated for the first
year in the SCAD cohort and the first year following a non-fatal event
during the follow-up period (AMI, ischaemic or haemorrhagic stroke)
with results reported as means and standard deviations, with medians
and interquartile ranges reported in the appendices. Observations
that were right censored for any reason other than mortality (i.e. those
for which the data are incomplete for the year of interest, either first
year with SCAD or first year following an event, but the reason for
incompleteness was not death) were excluded from the analysis.
A generalized linear model with a log link and gamma distribution was
used to estimate the impact of baseline covariates on costs in the first
year in the SCAD cohort to account for the non-linear impact of covariates
and the right skewness in cost data. Covariates were based on those used
by Rapsomaniki et al.,8 which developed a prognostic model for SCAD pa-
tients, on the assumption that predictors of costs were likely linked to
prognostic indicators. The covariates included the baseline diagnosis for
entry to SCAD, co-morbidities, age, gender, smoking status, and biomar-
kers. Models were fitted on five multiply-imputed data sets and estimates
combined using Rubin’s rules.19 The impact of covariates has been trans-
formed back onto the natural scale to allow for ease of interpretation.
Panel data methods with time invariant covariates were used to esti-
mate patient costs over each 90-day period. Also estimated were the
impact of events (non-fatal AMI, ischaemic and haemorrhagic stroke,
CVD- and non-CVD-related death) on the costs in the period of the
event and subsequent periods if the event was non-fatal. These costs
were then combined with a state transition Markov model to estimate
costs over a longer period. The model estimated the probabilities of,
and mean times to, the first events of non-fatal AMI, ischaemic or
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haemorrhagic stroke, CVD- and non-CVD-related death, and subse-
quent CVD or non-CVD death following a non-fatal first event. These
estimates were conditional on baseline covariates and were inferred
from patient-level costs, covariates, survival, and events experienced.
Full details of this model are available elsewhere with a brief description
given in the appendix.20 For the purpose of this article, the results of
costs over time are presented for patients based on average covariate
patterns for the 5-year risk deciles of a cardiovascular event. Discounted
costs are also presented using a discount rate of 3.5% per annum.21
Results
Cohort
In total, 94 966 patients were identified who met the inclusion cri-
teria, of which 44% were female. The mean age of men and women
included were 67 and 72 years, respectively. For the primary SCAD
diagnosis, 47.4% of patients had stable angina, 13.5% unstable angina,
6.7% ST-elevation MI (STEMI), 9.7% non-STEMI (NSTEMI), and
22.6% had CHD not otherwise specified. Full details of the cohort
can be found in Appendix Table A1.
Figure 1 summarizes the SCAD cohort and the patient numbers
used for each analysis.
Healthcare utilization
Table 1 reports healthcare utilization in the first year in the SCAD
cohort and in the first year following a non-fatal event during the
follow-up period (AMI, ischaemic or haemorrhagic stroke). In the first
year in the SCAD cohort, 20.5% of patients (n ¼ 17 532) were hos-
pitalized for CVD, and those who were hospitalized had a mean 1.9
stays (spells) in hospital with a mean length of stay of 4.6 days. In the
year following a non-fatal event during follow-up, 66% of patients
(n ¼ 4354) were hospitalized for CHD. These patients spent a
mean of 2.2 stays in hospital with a mean length of stay of 6.5 days.
In the first year in SCAD, patients had a mean of 10.8 primary care
appointments, and this increased to 13.7 in the first year following
a non-fatal event. In the first year of SCAD, 88.2% of patients were
taking cardiovascular medication, which decreased to 83.6% in the
year following a non-fatal event. In the first year of SCAD, 5.7% of
patients had a revascularization procedure, increasing to 13.5% of
patients in the first year following a non-fatal event.
Costs
Table 2 reports costs for hospitalizations, primary care appointments,
diagnostic tests, and drugs in patients in the first year in the SCAD co-
hort, and in the first year following a non-fatal event during follow-up
(MI, ischaemic or haemorrhagic stroke). The mean total healthcare
costs in the first year in the SCAD cohort were £3133 per patient,
of which 56.8% (£1780) and 70.2% (£2199) were related to CHD
and CVD, respectively. This estimate increased to £10 377 per pa-
tient in the year following a non-fatal event during follow-up, of which
66.2% (£6869) and 85.9% (£8916) were related to CHD and CVD,
respectively. The majority of healthcare costs were driven by hospi-
talizations (64.4% in the first year in the SCAD cohort and 84.2% in
the year following a non-fatal event during follow-up).
Figure 1 Stable coronary artery disease cohort.
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Cost predictors in the first year in the
stable coronary artery disease cohort
Figure 2 presents the results of the regression analysis showing the
incremental costs associated with different covariates and the asso-
ciated 95% confidence intervals (CI) for the first year in the SCAD
cohort. Non-CVD-related co-morbidities had the largest impact on
costs, with a history of renal disease associated with the largest in-
crement of £1998 per patient (95% CI £1715–£2297). A history of
heart failure resulted in an additional cost of £802 per patient (95%
CI £683–£920). Of the baseline diagnoses for entry to the SCAD
cohort, NSTEMI had the largest impact on cost with those patients
with NSTEMI costing an additional £656 per patient (95% CI £473–
£848) when compared with those with stable angina. Females were
significantly less costly than males, being female was associated with
a cost decrement of £549 per patient (95% CI 2£638 to 2£457).
Figures A1 and A2 in the appendix present the same results for CVD-
and CHD-related costs, respectively.
Estimated 90-day period and event costs
Tables A4, A5, and A6 in the appendix provide estimates of total
healthcare costs, CVD-related costs, and CHD-related costs,
respectively, for a 90-day period based on a range of baseline
characteristics. The tables also show the incremental costs in the
period of an event and in subsequent periods for non-fatal events.
For example, the background total healthcare costs for a male,
mean age 69 years, with no co-morbidities would be £341 in the first
90 days, increasing by £10 for each subsequent 90-day period. If the
patient had a non-fatal AMI, he would incur an incremental cost (on
top of the normal period cost of £372) of £5028 in the 90 days fol-
lowing the AMI with the incremental costs decreasing in subsequent
trimesters until 360 days after which there is an incremental cost of
£521 per 90 days suggesting significant ongoing lifetime costs of
events. Also of note, the incremental costs in the period of death
from CVD- and non-CVD-related causes were £2008 and £2240,
respectively.
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Table 1 Healthcare utilization in first year in the stable coronary artery disease cohort and first year following a
non-fatal event during follow-up (myocardial infarction, ischaemic or haemorrhagic stroke)
Resource use in first
year (n 5 85 702)
Resource in first year
following an event (n5 6599)
Mean (SD) Mean (SD)
Hospitalizations
Hospitalized (%) 37.6 (0.484) 83.5 (0.371)
Hospitalized for CVD (%) 27 (0.444) 80.2 (0.399)
Hospitalized for CHD (%) 20.5 (0.403) 66 (0.474)
Inpatient stays 0.875 (4.421) 2.364 (6.425)
Inpatient stays for CVD 0.503 (2.545) 1.931 (5.284)
Inpatient stays for CHD 0.343 (1.321) 1.434 (3.315)
With any hospitalization n ¼ 32 242 n ¼ 5512
Inpatient stays 2.325 (6.971) 2.83 (6.935)
Length of stay 6.717 (17.583) 14.857 (20.349)
With any hospitalization for CVD n ¼ 23 160 n ¼ 5291
Inpatient stays for CVD 1.862 (4.631) 2.408 (5.803)
Length of stay 7.516 (12.757) 15.541 (20.939)
With any hospitalization for CHD n ¼ 17 532 n ¼ 4354
Inpatient stays for CHD 1.674 (2.51) 2.174 (3.88)
Length of stay 4.579 (7.617) 6.515 (10.857)
Revascularizations
Any revascularization (%) 5.7 (0.232) 13.5 (0.341)
PCI (%) 3 (0.17) 9.1 (0.287)
CABG (%) 2.9 (0.169) 5 (0.218)
Primary care consultations 10.768 (10.857) 13.671 (15.407)
Drugs
Patients on any drugs (%) 91.3 (0.281) 85.1 (0.356)
Patients on CVD drugs (%) 88.2 (0.322) 83.6 (0.37)
Patients on anticoagulants (%) 8.7 (0.282) 14.7 (0.354)
Patients on ACEi or ARB (%) 47.7 (0.499) 61.5 (0.487)
Patients on anti-platelets (%) 65.6 (0.475) 76.3 (0.425)
Patients on b-blockers (%) 46 (0.498) 50.1 (0.5)
Patients on calcium channel blockers (%) 31.5 (0.464) 32.6 (0.469)
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Estimated costs over time for stable
coronary artery disease
Table 3 presents estimates of 5-year and lifetime costs (total and
CVD related, undiscounted and discounted) of the representative
patients for each risk group. The covariate profiles used are shown
in Appendix Table A7.
A patient with SCAD representative of the lowest risk decile
(5-year cardiovascular risk of 3.5% and a life expectancy of 26.8
years) would have expected undiscounted costs of £9335 over
5 years, of which 44.7 and 56.8% would be CHD and CVD related,
respectively; and undiscounted lifetime costs of £116 888, of which
40.1 and 61.5% would be CHD and CVD related, respectively.
A representative patient of the highest risk decile (5-year cardiovas-
cular risk of 44.2% and a life expectancy of 5.51 years) would have
expected undiscounted costs of £23 391 over 5 years, of which 53.0
and 72.9% would be CHD and CVD related, respectively; and life-
time undiscounted costs of £43 020, of which 51.9 and 72.5% would
be CHD and CVD related, respectively.
Figure 3 shows the predicted total, CVD-related, and CHD-
related costs and the survival curves over a 25-year period for
representative patients of risk deciles 1 (lowest risk), 4, 7, and 10
(highest risk). Higher risk patients with SCAD have higher initial
costs, which are overtaken by the lower risk patients as a result of
higher mortality in the higher risk groups resulting in less time to
accrue costs (5-year survivorship differs from 98.4% in risk decile
Figure 2 Forest plot of incremental costs associated with covariates.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Costs in first year in the stable coronary
artery disease cohort and in first year following an event
during follow-up (myocardial infarction, ischaemic or
haemorrhagic stroke)
Costs in
first year
(n 5 85 702)
Costs in first
year following
an event
(n 5 6599)
Mean (SD) Mean (SD)
Total costs
Total cost (£) 3133 (6101) 10 377 (12 260)
Total CVD cost (£) 2199 (4632) 8916 (10 930)
Total CHD costs (£) 1780 (3686) 6869 (9467)
Hospitalizations
Inpatient costs (£) 2018 (5632) 8744 (11 554)
Inpatient CVD costs (£) 1487 (4493) 7957 (10 796)
Inpatient CHD costs (£) 1067 (3548) 5910 (9338)
Primary care costs (£) 466 (463) 589 (629)
Diagnostic test costs (£) 141 (232) 228 (311)
Drugs
All drug costs (£) 508 (1548) 816 (3135)
CVD drug costs (£) 105 (113) 142 (175)
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1 to 40.7% in risk decile 10; and 25-year survivorship differs from
58.2% in risk decile 1 to 0.5% in risk decile 10).
Discussion
This study addresses a fundamental gap in knowledge relevant to
clinicians and policymakers: what is the clinical, health service, and
cost burden associated with SCAD? Using data from a large,
contemporary, and representative population of patients from the
England with SCAD, the analysis has shown that substantial health-
care costs are likely to be incurred as a result of improved ACS sur-
vivorship and the ageing population. Moreover, 5-year and lifetime
costs vary according to CVD risk, which may be readily predicted
from the baseline characteristics of patients that are routinely col-
lected. High-risk patients have considerably higher costs over the
initial 5 years but lower lifetime costs than lower risk patients as a
result of shorter life expectancy.
Patients with SCAD might be considered to have ‘fallen off the
radar’ of clinical interest. Current guidelines give little information
about how frequently and where such patients should be followed
up or if and how they should be risk stratified.5,6 Our results clearly
highlight the unmet need and the shortfalls of current ap-
proaches—with high use of primary care and frequent hospitaliza-
tions, there are considerable ongoing costs. The number of
primary care consultations, a mean of 10.8 per patient in the first
year in the SCAD cohort, is higher than previous estimates for the
overall population (5.5 per year).22 In the first year in the SCAD
cohort, over a third of patients were hospitalized (and 20.5% for
CHD reasons). This is substantially higher than recent estimates
for the general population in one area of the UK (14.9%),23 and
markedly higher than that in the general population for a similar
age (23.4 and 21.2% of 60- to 74-year-old males and females, re-
spectively, based on HES data).
Healthcare utilization is, however, insufficient as a metric of the
impact on the healthcare system. It is also important to consider
the cost imposed on the NHS associated with those resources as
this indicates the value of resources that cannot be devoted to
health-enhancing activities for other patients. Mean costs of
£3133 in the first year in the SCAD cohort are much higher than
those in patients without chronic conditions (£293), but compar-
able with other chronic conditions (e.g. diabetes £3036).23 Very
high costs in the first year following a non-fatal event during follow-
up (MI, ischaemic or haemorrhagic stroke) (£10 377) are reflective
of the healthcare utilization required to treat that event.
Patients were stratified by risk to understand the costs accrued
in greater detail. This higher resolution analysis allows the identifi-
cation of where novel treatments and health service interventions
have the greatest potential to be cost-effective. Non-CVD co-
morbidities were common and had a major influence on costs
with e.g. renal disease resulting in a mean extra cost of £1998
per patient in the first year of SCAD. This is an important finding
when the presence of multiple co-morbidities has been shown to
increase costs23 yet clinicians tend to focus only on single
diseases.24
The panel data analysis examined the average cost per 90-day
period with the disease and also the costs of events. The estimated
incremental cost of a non-fatal MI over 1 year (£7677 ignoring mor-
tality risk) was lower than some previous estimates from trial popu-
lations (e.g. among patients with stable angina the estimate of £9775
from the EUROPA trial).11 However, this lower estimate may be
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Table 3 Mean 5-year and lifetime costs for stable coronary artery disease patient population by cardiovascular risk
decile
Results Risk group
1 2 3 4 5 6 7 8 9 10
5-year riska (%) 3.46 5.43 6.95 8.53 10.36 12.57 15.64 20.07 27.23 44.18
Average age (years) 52 59 62 65 68 70 73 76 80 84
Life expectancy (years) 26.81 19.62 17.34 15.63 14.26 13.03 11.92 10.48 8.52 5.51
Total 5-year costs (£) 9335 11 200 12 308 13 512 14 644 15 930 17 660 19 609 21 617 23 391
Discounted total 5-year costsb (£) 8495 10 204 11 221 12 327 13 368 14 554 16 153 17 963 19 853 21 620
Total 5-year CVD costs (£) 5306 6959 7941 8954 9874 10 904 12 242 13 742 15 380 17 050
Discounted total 5-year CVD costsb (£) 4823 6338 7238 8168 9014 9962 11 197 12 589 14 126 15 759
Total 5-year CHD costs (£) 4172 5543 6354 7153 7867 8583 9449 10 385 11 376 12 392
Discounted total 5-year CHD costsb (£) 3801 5057 5801 6534 7191 7850 8651 9521 10 455 11 459
Total lifetime costs (£) 116 888 81 490 73 057 68 102 64 521 62 034 61 435 59 446 54 345 43 020
Discounted total lifetime costsb 62 210 50 864 48 046 46 535 45 429 44 785 45 283 44 903 42 436 35 549
Total lifetime CVD costs (£) 71 943 52 034 47 681 45 251 43 438 42 266 42 301 41 366 38 410 31 199
Discounted total lifetime CVD costsb (£) 37 857 32 331 31 288 30 896 30 584 30 531 31 211 31 281 30 024 25 801
Total lifetime CHD costs (£) 46 921 36 069 33 892 32 693 31 741 30 944 30 793 29 885 27 533 22 324
Discounted total lifetime CHD costsb (£) 25 316 22 868 22 639 22 672 22 657 22 619 22 946 22 778 21 646 18 522
aOf AMI, ischaemic or haemorrhagic stroke, or fatal CVD.
bDiscounted at a rate of 3.5% per annum to calculate the present value of the costs.
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reflective of less intensive use of healthcare resources in non-trial
settings and should provide a more accurate representation of costs
of these events in routine clinical practice. Estimated stroke costs in
the first year of the event (£8902 for ischaemic and £10 477 for
haemorrhagic stroke incremental to background costs) were similar
to those seen in other studies. For example, the OXVASC study
estimated mean total healthcare costs per patient in the first year
following stroke at £10524.25
Furthermore, a study of costs in the first year of SCAD and the
first year following an event is of limited use to decision-makers
who require more detailed information on the long-term costs
and consequences of SCAD. This can be seen from the panel data
analysis, which suggested ongoing long-term costs as a result of non-
fatal events. By estimating 5-year and lifetime costs by CVD risk
group, it was possible to examine the long-term cost implications
as a result of the disease and future events. In the shorter term of
5 years, which is shorter than the life expectancy of even the highest
risk group (although survivorship in this group was only 40.7% at
5 years), costs increased with cardiovascular risk, and were largely
driven by the high number of fatal and non-fatal events among these
patients. Over a lifetime, however, patients in the lower risk groups
eventually had substantially higher costs than higher risk patients,
primarily driven by greater life expectancy and, therefore, costs
being incurred over a much longer period. This is a key finding of
our research: increased survivorship as well as an increasingly
co-morbid and older population will result in significant future
healthcare costs. In turn, this has implications for the cost and
therefore the cost-effectiveness of established and new SCAD
treatments.
Many studies have attempted to address the burden of disease in
terms of health losses but fewer have examined the impact on finan-
cial costs of disease. Our research used SCAD as an exemplar in es-
timating resource use and costs from ‘real world’ electronic health
record data. The methods used here could be readily applied to
other chronic diseases to help produce evidence of their resource
and cost implications to better inform clinicians and decision-
makers. This would reduce uncertainty for those who need to fore-
cast future care needs and allow for better focused research and
development of new technologies and treatments for these chronic
diseases as well as resulting in better informed clinical decision-
making.
Limitations
While our study has a number of strengths including the multi-
source electronic health record linkage, there are a number of lim-
itations. In addition to being censored at 2010, after which there
have been further improvements in the care and survivorship of
SCAD, a key weakness of this study was the exclusion of outpatient
appointment costs that cannot currently be linked from HES. As a
result, the total healthcare costs of this population are underesti-
mated. Further disaggregation of primary care costs into CHD
and CVD related was not possible and therefore in each category
all primary care costs have been included and therefore are likely
overestimated. The estimation of lifetime costs has also involved ex-
trapolation over a longer time period than is currently observed in
the CALIBER data. This extrapolation is subject to considerable un-
certainty. The SCAD population is also inherently heterogeneous,
and there may be value in further disaggregation of the population
in future research.
Conclusions
Using a multi-source electronic health record approach, this study
provides, for the first time, estimates and predictors of contempor-
ary national healthcare utilization and costs in the first year of SCAD
and the first year following an event. It reveals that patients with
SCAD incur substantial healthcare utilization and costs, which
vary and may be predicted by 5-year CVD risk profiles. While high-
risk patients incur substantially higher costs over the short term
(5 years), low-risk patients incur higher lifetime costs as a result of
greater life expectancy. Improved cardiovascular survivorship and
an ageing UK population will require stratified care in anticipation
of the burgeoning economic demand. The methods used here could
Figure 3 Expected costs and survival over time for patients
representative of risk deciles 1, 4, 7, and 10. CHD, coronary heart
disease; CVD, cardiovascular disease; RG, risk decile.
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be readily applied to other chronic diseases to better inform clinical
decision-making.
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Appendix
Model description
A state transitionMarkov model was used to capture the natural his-
tory of SCAD patients. The model predicts time to first non-fatal
events (MI, ischaemic stroke or haemorrhagic stroke) and CVD
and non-CVDmortality (as a first event or following a non-fatal first
event). The model has a lifetime horizon and uses a 90-day cycle
length to capture the time varying and age-dependent nature of
risks. Risks of the five primary clinical endpoints (non-fatal MI, non-
fatal ischaemic stroke, non-fatal haemorrhagic stroke, and CVD and
non-CVD mortality) were estimated based on key prognostic
factors, including demographic measures, SCAD subtype, use of
long-acting nitrates, whether CABG or PCI was performed in the
6 months following CAD diagnosis, previous MI, smoking, blood
pressure, diagnosis of hypertension, diabetes, lipids, CVD co-
morbidities, non-CVD co-morbidities, psychosocial factors, and
clinically assessed biomarkers. Risk equations for the six subsequent
events, namely CVD and non-CVDmortality following non-fatal MI,
ischaemic stroke, and haemorrhagic strokewere estimated in a simi-
lar way. However, due to the greatly reduced numbers of events ob-
served, these were based only on sex and age at time of non-fatal
event. Non-CVD mortality beyond the maximum follow-up in the
CALIBER data set (10 years) was based on age– sex-specific
non-CVD mortality from national life tables. Costs are accrued
based on baseline covariate, events experienced, and time alive
with the costs based on the results detailed in this article. Full details
can be found in Asaria et al.20
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Figure A2 Forest plot of coronary heart disease costs.
Figure A1 Forest plot of cardiovascular disease costs.
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Table A1 Patient characteristics
Socio-demographic characteristics
Sex (% female) 44
Age (if male) (years) 67
Age (if female) (years) 72
Most deprived quintile (%) 20
Baseline diagnoses for entry to the SCAD cohort
NSTEMI (%) 10
STEMI (%) 7
Unstable angina (%) 14
Stable angina (%) 47
CHD not otherwise specified (%) 23
CVD risk factors
Current smoker (%) 35
Ex-smoker (%) 32
Never smoked (%) 33
Hypertension (%) 76
Diabetes (%) 16
CVD co-morbidities
Heart failure (%) 26
Atrial fibrillation (%) 15
Peripheral arterial disease (%) 8
Stroke (%) 9
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table A2 Healthcare utilization in first year with
stable coronary artery disease and first year following a
non-fatal event (myocardial infarction, ischaemic or
haemorrhagic stroke)
Mean (SD) Median (IQR)
Resource use in first year (n ¼ 85 702)
Hospitalizations
Hospitalized (%) 37.6 (0.484) 0 (0–1)
Hospitalized for CVD (%) 27 (0.444) 0 (0–1)
Hospitalized for CHD (%) 20.5 (0.403) 0 (0–1)
Inpatient stays 0.875 (4.421) 0 (0–3)
Inpatient stays for CVD 0.503 (2.545) 0 (0–2)
Inpatient stays for CHD 0.343 (1.321) 0 (0–2)
With any hospitalization (n ¼ 32 242)
Inpatient stays 2.325 (6.971) 1 (1–5)
Length of stay 6.717 (17.583) 3 (1–23)
With any hospitalization for CVD (n ¼ 23 160)
Inpatient stays for CVD 1.862 (4.631) 1 (1–4)
Length of stay 7.516 (12.757) 3.667 (1–26)
Continued
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table A2 Continued
Mean (SD) Median (IQR)
With any hospitalization for CHD (n ¼ 17 532)
Inpatient stays for CHD 1.674 (2.51) 1 (1–4)
Length of stay 4.579 (7.617) 2 (1–14.75)
Revascularizations
Any revascularization (%) 5.7 (0.232) 0 (0–1)
PCI (%) 3 (0.17) 0 (0–0)
CABG (%) 2.9 (0.169) 0 (0–0)
Primary care consultations 10.768 (10.857) 8 (0–30)
Drugs
Patients on any drugs (%) 91.3 (0.281) 1 (0–1)
Patients on CVD drugs (%) 88.2 (0.322) 1 (0–1)
Patients on anticoagulants (%) 8.7 (0.282) 0 (0–1)
Patients on ACEi or ARB (%) 47.7 (0.499) 0 (0–1)
Patients on anti-platelets (%) 65.6 (0.475) 1 (0–1)
Patients on b-blockers (%) 46 (0.498) 0 (0–1)
Patients on calcium channel
blockers (%)
31.5 (0.464) 0 (0–1)
Resource in first year following an event (n ¼ 6599)
Hospitalizations
Hospitalized (%) 83.5 (0.371) 1 (0–1)
Hospitalized for CVD (%) 80.2 (0.399) 1 (0–1)
Hospitalized for CHD (%) 66 (0.474) 1 (0–1)
Inpatient stays 2.364 (6.425) 1 (0–6)
Inpatient stays for CVD 1.931 (5.284) 1 (0–5)
Inpatient stays for CHD 1.434 (3.315) 1 (0–4)
With any hospitalization (n ¼ 5512)
Inpatient stays 2.83 (6.935) 2 (1–6)
Length of stay 14.857 (20.349) 8.5 (1.5–50.5)
With any hospitalization for CVD (n ¼ 5291)
Inpatient stays for CVD 2.408 (5.803) 2 (1–5)
Length of stay 15.541 (20.939) 9 (2–52)
With any hospitalization for CHD (n ¼ 4354)
Inpatient stays for CHD 2.174 (3.88) 1 (1–5)
Length of stay 6.515 (10.857) 3.5 (1–21.5)
Revascularizations
Any revascularization (%) 13.5 (0.341) 0 (0–1)
PCI (%) 9.1 (0.287) 0 (0–1)
CABG (%) 5 (0.218) 0 (0–1)
Primary care consultations 13.671 (15.407) 11 (0–38)
Drugs
Patients on any drugs (%) 85.1 (0.356) 1 (0–1)
Patients on CVD drugs (%) 83.6 (0.37) 1 (0–1)
Patients on anticoagulants (%) 14.7 (0.354) 0 (0–1)
Patients on ACEi or ARB (%) 61.5 (0.487) 1 (0–1)
Patients on anti-platelets (%) 76.3 (0.425) 1 (0–1)
Patients on b-blockers (%) 50.1 (0.5) 1 (0–1)
Patients on calcium channel
blockers (%)
32.6 (0.469) 0 (0–1)
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Table A3 Costs in first year with stable coronary artery disease and in first year following an event (myocardial
infarction, ischaemic of haemorrhagic stroke)
Mean (SD) (£) Median (IQR) (£)
Costs in first year (n ¼ 85 702)
Total costs
Total cost 3133 (6101) 1149 (43–12 641)
Total CVD cost 2199 (4632) 735 (0–10 274)
Total CHD costs 1780 (3686) 685 (0–8413)
Hospitalizations
Inpatient costs 2018 (5632) 0 (0–10 603)
Inpatient CVD costs 1487 (4493) 0 (0–9333)
Inpatient CHD costs 1067 (3548) 0 (0–7284)
Primary care costs 466 (463) 361 (0–1291)
Diagnostic test costs 141 (232) 70 (0–538)
Drugs
All drug costs 508 (1548) 209 (0–1698)
CVD drug costs 105 (113) 84 (0–272)
Costs in first year following an event (n ¼ 6599)
Total costs
Total cost 10 377 (12 260) 6855 (580–30 755)
Total CVD cost 8916 (10 930) 5819 (384–27 279)
Total CHD costs 6869 (9467) 3972 (159–23 336)
Hospitalizations
Inpatient costs 8744 (11 554) 5421 (0–27 436)
Inpatient CVD costs 7957 (10 796) 4871 (0–25 843)
Inpatient CHD costs 5910 (9338) 3127 (0–22 020)
Primary care costs 589 (629) 456 (0–1664)
Diagnostic test costs 228 (311) 131 (0–806)
Drugs
All drug costs 816 (3135) 293 (0–2924)
CVD drug costs 142 (175) 110 (0–376)
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Table A4 Total healthcare costs per 90-day period
Coefficient
(£)
Standard
error
Lower 95%
CI (£)
Upper 95%
CI (£)
Background cost per 90 days
Baseline (for a man aged 69 with stable angina and no other co-morbidities) 341 10.15 322 361
Baseline age (centred) 7 0.42 6 7
Female 27 10.09 226 13
Increase per 90 days 10 0.18 10 11
SCAD diagnosis (relative to stable angina)
Other CHD 220 12.40 244 5
NSTEMI 157 18.37 121 193
STEMI 226 21.48 268 17
Unstable angina 153 14.92 124 183
CVD co-morbidities
History of heart failure 364 12.23 340 388
History of atrial fibrillation 186 14.32 158 214
History of PAD 327 17.80 292 362
Non-CVD co-morbidities
Diabetes 338 13.71 312 365
History of liver disease 530 50.70 431 629
History of COPD 231 11.58 208 254
History of cancer 331 17.51 296 365
History of renal disease 756 20.93 715 797
Incremental cost of non-fatal MI
Cost in first 90-day period 5028 34.41 4961 £5096
Cost in second 90-day period 1282 36.84 1210 £1354
Cost in third 90-day period 675 39.15 598 £751
Cost in fourth 90-day period 692 40.84 612 £772
Cost in subsequent 90-day periods 521 18.64 484 £557
Additional incremental cost of non-fatal MI for patients with diabetes
Additional cost in first 90-day period 776 75.79 627 924
Cost in second 90-day period 1100 81.56 940 1260
Cost in third 90-day period 785 87.01 614 955
Cost in fourth 90-day period 550 90.87 372 728
Cost in subsequent 90-day periods 369 42.16 286 451
Incremental cost of non-fatal ischaemic stroke
Cost in first 90-day period 6215 36.01 6144 6285
Cost in second 90-day period 1239 38.03 1164 1313
Cost in third 90-day period 795 41.05 714 875
Cost in fourth 90-day period 654 43.12 569 738
Cost in subsequent 90-day periods 564 19.97 525 604
Incremental cost of non-fatal haemorrhagic stroke
Cost in first 90-day period 7011 125.41 6765 7257
Cost in second 90-day period 1767 138.80 1495 2039
Cost in third 90-day period 947 155.22 643 1252
Cost in fourth 90-day period 751 165.14 428 1075
Cost in subsequent 90-day periods 927 74.20 782 1073
Cost of fatal events
Fatal CVD event 2008 24.88 1960 2057
Fatal non-CVD event 2240 20.16 2201 2280
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Table A5 Total cardiovascular disease-related healthcare costs
Coefficient
(£)
Standard
error
Lower 95%
CI (£)
Upper 95%
CI (£)
Background cost per 90 days
Baseline (for a man aged 69 with stable angina and no other co-morbidities) 224 7.74 209 239
Baseline age (centred) 6 0.32 6 7
Female 223 7.65 238 28
Increase per 90 days 7 0.15 6 7
SCAD diagnosis (relative to stable angina)
Other CHD 2 9.39 216 21
NSTEMI 145 13.66 119 172
STEMI 29 15.77 22 60
Unstable angina 125 11.32 103 147
CVD co-morbidities
History of heart failure 248 9.29 230 266
History of atrial fibrillation 221 10.90 199 242
History of PAD 242 13.53 216 269
Non-CVD co-morbidities
Diabetes 194 10.43 173 214
History of liver disease 279 38.68 203 355
History of COPD 142 8.79 124 159
History of cancer 154 13.34 128 180
History of renal disease 418 16.07 386 449
Incremental cost of non-fatal MI
Cost in first 90-day period 4854 29.55 4796 4911
Cost in second 90-day period 1209 31.64 1147 1271
Cost in third 90-day period 640 33.63 574 706
Cost in fourth 90-day period 675 35.08 606 744
Cost in subsequent 90-day periods 481 15.64 451 512
Additional incremental cost of non-fatal MI for patients with diabetes
Additional cost in first 90-day period 674 65.05 546 801
Cost in second 90-day period 1042 70.02 904 1179
Cost in third 90-day period 660 74.71 514 807
Cost in fourth 90-day period 403 78.04 250 556
Cost in subsequent 90-day periods 280 35.33 210 349
Incremental cost of non-fatal ischaemic stroke
Cost in first 90-day period 5957 30.95 5897 6018
Cost in second 90-day period 1151 32.69 1087 1215
Cost in third 90-day period 675 35.29 606 744
Cost in fourth 90-day period 539 37.08 466 612
Cost in subsequent 90-day periods 448 16.86 415 481
Incremental cost of non-fatal haemorrhagic stroke
Cost in first 90-day period 6836 107.73 6625 7047
Cost in second 90-day period 1517 119.28 1284 1751
Cost in third 90-day period 585 133.45 324 847
Cost in fourth 90-day period 393 142.02 115 671
Cost in subsequent 90-day periods 670 62.69 547 792
Cost of fatal events
Fatal CVD event 2071 21.30 2029 2113
Fatal non-CVD event 1737 17.28 1703 1771
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Table A6 Total coronary heart disease-related healthcare costs
Coefficient
(£)
Standard
error
Lower 95%
CI (£)
Upper 95%
CI (£)
Background cost per 90 days
Baseline (for a man aged 69 with stable angina and no other co-morbidities) 179 5.93 167 191
Baseline age (centred) 4 0.24 4 5
Female 223 5.85 235 212
Increase per 90 days 4 0.12 3 4
SCAD diagnosis (relative to stable angina)
Other CHD 82 7.17 68 97
NSTEMI 219 10.49 198 239
STEMI 111 12.04 88 135
Unstable angina 163 8.65 146 179
CVD co-morbidities
History of heart failure 143 7.11 129 157
History of atrial fibrillation 84 8.34 67 100
History of PAD 161 10.35 141 181
Non-CVD co-morbidities
Diabetes 144 7.98 128 160
History of liver disease 198 29.62 140 256
History of COPD 117 6.72 104 131
History of cancer 107 10.21 87 127
History of renal disease 201 12.34 176 225
Incremental cost of non-fatal MI
Cost in first 90-day period 4658 23.69 4612 4705
Cost in second 90-day period 1166 25.36 1116 1215
Cost in third 90-day period 590 26.96 538 643
Cost in fourth 90-day period 642 28.13 587 697
Cost in subsequent 90-day periods 475 12.40 451 500
Additional incremental cost of non-fatal MI for patients with dibetes
Additional cost in first 90-day period 643 52.14 541 745
Cost in second 90-day period 792 56.13 682 902
Cost in third 90-day period 701 59.90 584 819
Cost in fourth 90-day period 330 62.57 207 453
Cost in subsequent 90-day periods 269 28.01 215 324
Incremental cost of non-fatal ischaemic stroke
Cost in first 90-day period 3029 24.82 2981 3078
Cost in second 90-day period 620 26.22 568 671
Cost in third 90-day period 415 28.31 359 470
Cost in fourth 90-day period 262 29.74 203 320
Cost in subsequent 90-day periods 256 13.42 230 282
Incremental cost of non-fatal haemorrhagic stroke
Cost in first 90-day period 2874 86.38 2704 3043
Cost in second 90-day period 790 95.66 602 977
Cost in third 90-day period 218 107.04 8 428
Cost in fourth 90-day period 301 113.92 77 524
Cost in subsequent 90-day periods 251 49.89 154 349
Cost of fatal events
Fatal CVD event 1407 17.06 1374 1441
Fatal non-CVD event 1068 13.84 1040 1095
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Table A7 Covariate profiles based on deciles of 5-year risk
Patient average covariate profiles based on deciles of 5-year risk of composite CVD first event
Risk decile 1 2 3 4 5 6 7 8 9 10
5-year risk (average) 3.69% 5.70% 7.37% 9.15% 11.20% 13.71% 17.14% 22.14% 30.42% 52.37%
Re-calculated 5-year risk 3.46% 5.43% 6.95% 8.53% 10.36% 12.57% 15.64% 20.07% 27.23% 44.18%
Socio-demographic characteristics
Sex (female) 64% 48% 42% 39% 37% 37% 38% 42% 44% 46%
Age (if male) 49 55 59 62 65 67 71 74 77 81
Age (if female) 53 62 67 70 73 75 78 80 83 87
Age (weighted average) 52 59 62 65 68 70 73 76 80 84
Most deprived quintile 15% 17% 18% 19% 20% 21% 21% 22% 22% 24%
SCAD diagnosis and severity
Other CHD 11% 17% 20% 22% 24% 24% 25% 26% 25% 20%
NSTEMI 0% 1% 3% 5% 8% 10% 12% 17% 23% 43%
STEMI 1% 4% 8% 12% 13% 14% 13% 9% 6% 4%
Unstable angina 10% 13% 12% 12% 12% 12% 13% 15% 17% 15%
Stable angina 78% 65% 56% 49% 43% 39% 37% 34% 29% 18%
PCI in last 6 months 9% 12% 13% 14% 13% 13% 11% 9% 6% 4%
CABG in last 6 months 9% 7% 6% 5% 5% 4% 4% 3% 2% 1%
Previous/recurrent MI 2% 6% 10% 14% 18% 23% 26% 29% 32% 43%
Use of nitrates 10% 16% 19% 21% 24% 28% 33% 37% 43% 56%
CVD risk factors
Current smoker 31% 35% 36% 37% 38% 38% 37% 35% 32% 30%
Ex-smoker 27% 30% 31% 32% 32% 33% 34% 34% 34% 34%
Never smoked 41% 35% 33% 31% 30% 29% 29% 31% 33% 36%
Hypertension 69% 70% 71% 71% 72% 74% 76% 79% 83% 87%
Diabetes 4% 8% 10% 12% 14% 16% 18% 21% 24% 32%
Total cholesterol (mmol/L) 4.95 4.91 4.84 4.79 4.74 4.74 4.70 4.68 4.64 4.54
HDL (mmol/L) 1.41 1.37 1.35 1.35 1.35 1.35 1.36 1.37 1.37 1.35
CVD co-morbidities
Heart failure 5% 7% 9% 12% 15% 19% 27% 37% 52% 73%
Peripheral arterial disease 1% 2% 3% 4% 6% 8% 10% 13% 16% 25%
Atrial fibrillation 3% 5% 7% 9% 10% 13% 16% 21% 29% 43%
Stroke 0% 1% 1% 2% 3% 5% 8% 14% 22% 39%
Non-CVD co-morbidities
Chronic kidney disease 2% 2% 3% 4% 4% 5% 7% 9% 12% 20%
Chronic obstructive pulmonary disease 20% 20% 20% 21% 22% 23% 25% 27% 28% 30%
Cancer 4% 5% 6% 7% 8% 9% 11% 13% 14% 12%
Chronic liver disease 0% 1% 1% 1% 1% 1% 1% 1% 1% 1%
Psychosocial characteristics
Depression at diagnosis 20% 17% 15% 15% 14% 14% 15% 17% 18% 21%
Anxiety at diagnosis 7% 6% 6% 7% 7% 7% 8% 8% 10% 12%
Biomarkers
Heart rate (b.p.m.) 72 71 71 71 71 71 72 73 74 76
Creatinine (mmol/L) 88 92 95 96 98 100 101 104 109 125
White cell count (109/L) 6.81 7.05 7.19 7.31 7.44 7.54 7.62 7.76 7.88 8.22
Haemoglobin (g/100 mL) 14.26 14.26 14.16 14.05 13.88 13.70 13.48 13.16 12.81 12.20
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